Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of TQB2450 with or without anlotinib versus placebo after chemoradiotherapy in unresectable stage III non-small cell lung cancer
CTR20200299Phase 3Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- May 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of benmelstobart, anlotinib in non-small cell lung cancer (NSCLC), sponsored by Nanjing Shunxin Pharmaceutical. Started May 2020; status: active.
02
Drugs
benmelstobartanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200299.